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concise communication

Severity of Clostridium difficile–
Associated Disease (CDAD)
in Allogeneic Stem Cell Transplant
Recipients: Evaluation of a CDAD
Severity Grading System
Erik R. Dubberke, MD; Justin Sadhu, BS;
Robert Gatti, BS; Kimberly A. Reske, MPH;
John F. DiPersio, MD, PhD; Steven M. Devine, MD;
Victoria J. Fraser, MD
The purpose of this study was to develop and test a Clostridium
difficile–associated disease (CDAD) grading system based on presenting symptoms in allogeneic stem cell transplant recipients. Patients with severe CDAD had significantly shorter median survival
times and more adverse outcomes than patients with mild or moderate CDAD.
Infect Control Hosp Epidemiol 2007; 28:208-211

Clostridium difficile–associated disease (CDAD) is the most
common infectious cause of healthcare-associated diarrhea.1
Allogeneic stem cell transplant recipients may be at increased
risk for severe CDAD because of their immunocompromised
state. However, studies of CDAD in hematopoietic cell transplantation patients disagree about the incidence of, severity
of, and risk factors for CDAD.2-10 A lack of differentiation
between mild cases and severe cases of CDAD may explain
some of these discrepancies. To address this deficiency and
to further study CDAD outcomes among allogeneic stem cell
transplant recipients, we developed and validated a grading
system for CDAD severity using a modified version of the
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0 (CTCAE) and based on the presenting clinical CDAD symptoms.

me th ods
The study was conducted at Barnes-Jewish Hospital, a 1,250bed, tertiary care hospital in St. Louis, Missouri. A retrospective cohort study was performed that included all allogeneic stem cell transplant recipients who developed their
first episode of CDAD between August 1, 2001, and July 31,
2003. Cases were identified prospectively by the infection control department. Patients were excluded if they had a history
of CDAD before the study period. A case of CDAD was
defined by a stool toxin assay positive for C. difficile toxin
(Tech Lab). The decision to order a C. difficile toxin assay
was made by the patient’s treating physician on the basis of
the patient’s symptoms and risk factors. In addition, the microbiology laboratory tests stool samples for C. difficile only

if the stool sample conforms to the container in which it is
sent (ie, is unformed).
Patients’ medical records were reviewed to collect information on demographic characteristics, underlying disease
status, symptoms, infections, complications, medications received, and outcomes. Infections were defined using the Centers for Disease Control and Prevention National Nosocomial
Infections Surveillance System definitions.11,12 Patients were
followed up for 180 days after the date of CDAD diagnosis
to identify infections and determine mortality. Diarrhea was
defined as 3 or more loose bowel movements per day, for at
least 48 hours. Response to CDAD therapy was defined as
either a decrease in diarrhea by half or resolution of ileus
and resolution of any other associated symptoms.
The CDAD severity grading system was developed by modifying the criteria for grading diarrhea and colitis in the
CTCAE. The CTCAE is a standardized method of reporting
adverse events in cancer patients.13 Hypothermia (temperature of 35.6⬚C or less, or 35.9⬚C or less for more than an
hour) was added as a criterion for grade 3 colitis. The nursing
notes for the transplantation ward include an intake and output assessment. Because intestinal output is recorded only if
diarrhea is present, total daily intestinal output was included
in the determination of diarrhea severity: 500 mL or less of
intestinal output per day was included in the definition of
grade 1 diarrhea; 501 to 1,000 mL in the definition of grade
2; 1,001 to 2,000 mL in grade 3; and more than 2,000 mL
in grade 4. Mild CDAD was defined as grade 1 diarrhea and/
or colitis. Moderate CDAD was defined as grade 2 diarrhea
and/or colitis. Severe CDAD was defined as grade 3 or higher
diarrhea and/or colitis. All symptoms had to be present within
48 hours of the time CDAD was diagnosed to be included
in the grading scale. For statistical analyses, mild and moderate cases were grouped together and compared with the
severe cases.
Statistical analyses were performed with SPSS statistical
software, version 12.0 for Windows (SPSS). Statistical tests
used included the x2, Fisher exact, Mann-Whitney U, and
Kaplan-Meier tests. P values less than or equal to .05 were
considered statistically significant. The Washington University
Human Studies Committee approved this study.

re s u l t s
Thirty-seven allogeneic stem cell transplant recipients met the
inclusion criteria. Sixteen patients (43%) were classified as
having mild or moderate CDAD and 21 (57%) as having
severe CDAD. No significant differences at baseline were
noted between patients who developed mild or moderate
CDAD and patients who developed severe CDAD with respect
to demographic characteristics, underlying disease, reason for
admission, transplant donor source (sibling vs unrelated),

cdad severity grading system

table.
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Outcomes for Patients With Clostridium difficile–Associated Disease (CDAD)

Outcome
Therapy
Responded to therapy
Responded to therapy after 12 days
Treated with Mtz only
Treated with Mtz plus Vm or Vm only
Duration of treatment, mean days
CDAD relapsea
Acute renal failure
(creatinine level, x2.0 mg/dL)
Acute liver dysfunction
(total bilirubin level, x4.0 mg/dL)
BSI rate, cases per 1,000 patient-daysb
BSI due to enteric organismbc

Patients with mild
or moderate CDAD
(N p 16)
15
5
11
4

(94)
(31)
(69)
(25)
13
5 (31)

Patients with
severe CDAD
(N p 21)
19
14
8
12

P

(91)
(67)
(38)
(57)
16
5 (36)

1.0
.05
.06
.05
.30
1.0

0 (0)

7 (33)

.01

1 (6)
5.7
4 (31)

5 (24)
11.5
14 (82)

.20
.06
.004

note.

Data are no. (%) of patients, unless indicated otherwise. BSI, bloodstream infection; Mtz,
metronidazole; Vm, vancomycin.
a
Among the patients alive at discharge (mild to moderate CDAD, 16 patients; severe CDAD, 14
patients).
b
Includes only BSI after onset of CDAD (relative rate, 2.0 [95% confidence interval, 1.0-4.1]).
c
Of the total number of BSIs (patients with mild to moderate CDAD, 13 cases of BSI; patients with
severe CDAD, 17 cases of BSI). BSI in patients with mild or moderate CDAD was caused by coagulasenegative Staphylococcus (6 cases), Klebsiella pneumoniae (2), Klebsiella oxytoca, Escherichia coli, methicillin-resistant Staphylococcus aureus, viridans group Streptococcus, and Stomatococcus species. BSIs in
patients with severe CDAD were caused by vancomycin-resistant enterococci (5 cases), coagulasenegative Staphylococcus (3), Enterococcus faecalis (2), Candida albicans (2), Candida tropicalis (2), K.
pneumoniae, K. oxytoca, and Pseudomonas aeruginosa.

days since transplantation, graft-versus-host disease, neutropenia at the time of CDAD diagnosis, or number of days
hospitalized before CDAD. The CDAD symptoms seen most
frequently within 48 hours of diagnosis were diarrhea (in 31
patients [84%]), fever (in 13 [35%]), and abdominal pain
(in 9 [24%]).
Patients with severe CDAD had significantly more adverse
outcomes than did patients with mild or moderate CDAD
(Table). Patients with severe CDAD were more likely to be
treated with metronidazole and vancomycin or vancomycin alone than were patients with mild or moderate CDAD
(P p .05). Compared with patients with mild or moderate
CDAD, a larger number of patients with severe CDAD required more than 2 days to respond to therapy (P p .05),
and more of these patients had acute renal failure after the
onset of CDAD (P p .01). Patients with severe CDAD had
a higher rate of bloodstream infection (BSI) after CDAD (11.5
vs 5.7 cases per 1,000 patient-days; relative rate, 2.0 [95%
confidence interval, 1.0-4.1]). Significantly more cases of BSI
due to enteric organisms occurred among patients with severe
CDAD than among patients with mild or moderate CDAD
(P p .004). The median survival time after CDAD was 266
days for patients with mild or moderate CDAD and 55 days
for patients with severe CDAD (log-rank P p .003) (Figure).

discussion
This study is the first, to our knowledge, to provide a method
for grading CDAD severity in allogeneic stem cell transplant
recipients. Previously published CDAD severity grading systems were developed on the basis of outcomes and characteristics seen in patients with CDAD throughout their clinical
course.14,15 The grading system presented herein was developed on the basis of clinical presentation (symptoms present
within 48 hours before or after CDAD diagnosis). Application
of this system identified patients at increased risk for adverse
events associated with CDAD. Patients with severe CDAD
were more likely to be treated with vancomycin or metronidazole plus vancomycin than were patients with mild or
moderate CDAD. Metronidazole is first-line therapy for
CDAD at our institution, and vancomycin is used for severe
or refractory CDAD. The increased use of vancomycin among
patients with severe CDAD suggests that the treating physicians perceived these patients’ symptoms to be more severe
than those of other patients or refractory to metronidazole
therapy. Significantly more patients with severe CDAD required more than 2 days to respond to antimicrobial therapy
and experienced acute renal failure after CDAD onset than
did patients with mild or moderate CDAD.
Significantly more cases of BSI caused by enteric organisms
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hypothesis (ie, more cases mistakenly categorized as mild or
moderate).
Despite the small sample size and the complex nature of
the study population, this CDAD severity grading system
identified patients at high risk for adverse outcomes after
CDAD based on presenting symptoms. In addition, an important benefit of this system is the ease with which it can
be used. Because both the incidence of CDAD and the size
of the immunocompromised population are increasing, a
CDAD severity grading system such as the one presented
herein may become critical to early identification of patients
at high risk for adverse events associated with CDAD. Prospective validation of this system is needed.
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